中华皮肤科杂志 ›› 2004, Vol. 37 ›› Issue (2): 77-79.

• 论著 • 上一篇    下一篇

系统性红斑狼疮患者血清基质金属蛋白酶-9的检测

殷文浩, 鲍彰, 郑敏   

  1. 浙江大学医学院附属第二医院皮肤科 杭州 310009
  • 收稿日期:2003-03-31 出版日期:2004-02-15 发布日期:2004-02-15
  • 基金资助:
    浙江省科技计划项目(2003C23012)

Serum Levels of Matrix Metalloproteinases-9 in Patients with Systemic Lupus Erythematosus

YIN Wen-hao, BAO Zhang, ZHENG Min   

  1. Department of Dermatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China
  • Received:2003-03-31 Online:2004-02-15 Published:2004-02-15

PDF (PC)

120

赞

摘要： 目的 检测系统性红斑狼疮(SLE)患者血清基质金属蛋白酶-9(MMP-9)和金属蛋白酶组织抑制物-1(TIMP-1)水平并探讨其临床意义。方法 MMP-9和TIMP-1检测采用ELISA方法。结果 ①SLE患者血清MMP-9平均中位数水平为65.00ng/mL显著低于正常人对照组267.50ng/mL(P<0.001)。②SLE患者中,血清MMP-9水平活动组低于非活动组(P<0.05),肾损组低于非肾损组(P<0.01),低补体C3血症者低于无低补体C3血症者(P<0.05),低血清白蛋白血症者低于非低白蛋白血症者(P<0.05),外周血白细胞计数降低者低于无白细胞降低者(P<0.01)。③糖皮质激素治疗后患者MMP-9水平高于治疗前(P<0.05)。④患者MMP-9水平与SLE疾病活动指数(SLEDAI)呈负相关(P<0.01),与C3(P<0.05)、白细胞(P<0.01)、白蛋白/球蛋白比值(P<0.05)呈正相关。⑤血清TIMP-1水平在SLE组与对照组、SLE各相关组之间差异均无显著性。结论 MMP-9可能参与SLE发病机制。

关键词: 红斑狼疮,系统性, 明胶酶B, 金属蛋白酶1组织抑制剂

Abstract: Objective To determine the serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with systemic lupus erythematosus (SLE) and their clinical significances. Methods The serum concentrations of MMP-9 and TIMP-1 were measured by ELISA in 46 patients with SLE and age-and sex-matched normal controls. Results ①Serum levels of MMP-9 was significantly decreased in patients with SLE compared with those in normal controls (P<0.001). ②In SLE patients, serum levels of MMP-9 were significantly decreased in patients with active diseases and renal involvement compared with those in patients with inactive diseases and no renal involvement (P<0.05 and P<0.01, respectively). Serum levels of MMP-9 were also significantly decreased in SLE patients with the following abnormalities:decreased C3 (P<0.05), hypoalbuminemia (P<0.05) and leucocytopenia (P<0.01). ③Serum levels of MMP-9 were markedly increased in 11 patients after treatment with steroids (P<0.05). ④Serum levels of MMP-9 had negative correlation with SLEDAI scores (P<0.01), and positive correlation with serum C3 levels (P<0.05), white blood cell counts (P<0.01), and serum albumin-globulin ratio (P<0.05). ⑤No significant differences of serum TIMP-1 levels were found between patients with SLE and healthy controls, and between different groups of SLE. Conclusions The results suggest that MMP-9 may play certain roles in the pathogenesis of SLE. Serum MMP-9 level could be used as an indicator for measuring disease activity of SLE, observing renal involvement and evaluation of therapeutic efficacy of steroids.

Key words: Lupus erythematosus, systemic, Gelatinase B, Tissue inhibitor of metalloproteinase-1